Confo Therapeutics awarded € 1 million VLAIO grant for pre-clinical development of CFTX-1554, an AT2R modulator for the treatment of neuropathic pain
Ghent, Belgium: 30 March 2021 – Confo Therapeutics announced today that it has been awarded a € 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, Confo’s lead candidate for neuropathic pain, which was initially discovered under a previous VLAIO research grant.
Confo is developing CFTX-1554 based on its promise as a potential treatment for patients living with peripheral neuropathic pain, a debilitating condition for which current treatment methods are ineffective or often result in severe side-effects or even addiction. The grant covers clinical trial application (CTA)-enabling studies to further characterize the pharmacology and safety of CFTX-1554 and the development of appropriate manufacturing protocols, as well as translational biomarker studies to examine the mechanism of action of AT2R modulation.
More info on Confo Therapeutics’ website.